Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Palvella Therapeutics, Inc. - Common Stock
(NQ:
PVLA
)
120.30
-7.04 (-5.53%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Palvella Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
October 15, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
October 13, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
October 12, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
September 28, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
September 09, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
September 02, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
August 31, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 05, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 04, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
July 30, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
July 28, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
June 30, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
June 29, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
June 22, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
June 03, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 02, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
May 27, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
May 21, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular
May 20, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
May 15, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
May 13, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 07, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
May 04, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
April 30, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
April 20, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
April 13, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
April 07, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
March 31, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
March 30, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
March 27, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
